NCT00113373View on ClinicalTrials.gov

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
DRUG

lapatinib ditosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00113373 - Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | Biotech Hunter | Biotech Hunter